WallStreetZenWallStreetZen

NASDAQ: DRIO
Dariohealth Corp Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for DRIO

Based on 1 analyst offering 12 month price targets for Dariohealth Corp

Min Forecast
$2.00+177.78%
Avg Forecast
$2.00+177.78%
Max Forecast
$2.00+177.78%

Should I buy or sell DRIO stock?

Based on 1 analyst offering ratings for Dariohealth Corp.

Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although DRIO's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates DRIO as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their DRIO stock forecasts and price targets.

DRIO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-03-11

1 of 1

Forecast return on equity

Is DRIO forecast to generate an efficient return?

Company
N/A
Industry
-12.1%
Market
63.18%

Forecast return on assets

Is DRIO forecast to generate an efficient return on assets?

Company
N/A
Industry
12.53%

DRIO earnings per share forecast

What is DRIO's earnings per share in the next 2 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$1.06
Avg 2 year Forecast
-$1.01

DRIO revenue forecast

What is DRIO's revenue in the next 2 years based on estimates from 1 analyst?

Avg 1 year Forecast
$32.0M+18.42%
Avg 2 year Forecast
$38.1M+40.79%
DRIO's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

DRIO revenue growth forecast

How is DRIO forecast to perform vs Diagnostics & Research companies and vs the US market?

Company
18.66%
Industry
5.23%
Market
11%
DRIO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
DRIO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

DRIO vs Diagnostic & Research Stocks

TickerPricePrice TargetUp/downsideConsensus
DRIO$0.72$2.00+177.78%Strong Buy
ENZ$0.49N/AN/A
PRPO$7.13N/AN/A
ME$1.84N/AN/A
PRPH$0.40N/AN/A
View Top Diagnostic & Research Stocks

Dariohealth Stock Forecast FAQ

Is Dariohealth Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: DRIO) stock is to Strong Buy DRIO stock.

Out of 1 analyst, 1 (100%) are recommending DRIO as a Strong Buy, 0 (0%) are recommending DRIO as a Buy, 0 (0%) are recommending DRIO as a Hold, 0 (0%) are recommending DRIO as a Sell, and 0 (0%) are recommending DRIO as a Strong Sell.

If you're new to stock investing, here's how to buy Dariohealth stock.

What is DRIO's earnings growth forecast for 2025-2026?

(NASDAQ: DRIO) Dariohealth's forecast annual earnings growth rate of N/A is not forecast to beat the US Diagnostics & Research industry's average forecast earnings growth rate of 32.47%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 24.22%.

Dariohealth's earnings in 2025 is -$40,982,000.On average, 1 Wall Street analyst forecast DRIO's earnings for 2025 to be -$44,061,037, with the lowest DRIO earnings forecast at -$44,061,037, and the highest DRIO earnings forecast at -$44,061,037.

In 2026, DRIO is forecast to generate -$41,982,686 in earnings, with the lowest earnings forecast at -$41,982,686 and the highest earnings forecast at -$41,982,686.

What is DRIO's revenue growth forecast for 2025-2026?

(NASDAQ: DRIO) Dariohealth's forecast annual revenue growth rate of 18.66% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.23%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11%.

Dariohealth's revenue in 2025 is $27,040,000.On average, 1 Wall Street analysts forecast DRIO's revenue for 2025 to be $1,330,975,852, with the lowest DRIO revenue forecast at $1,330,975,852, and the highest DRIO revenue forecast at $1,330,975,852.

In 2026, DRIO is forecast to generate $1,582,456,299 in revenue, with the lowest revenue forecast at $1,582,456,299 and the highest revenue forecast at $1,582,456,299.

What is DRIO's forecast return on assets (ROA) for 2025-2027?

(NASDAQ: DRIO) forecast ROA is N/A, which is lower than the forecast US Diagnostics & Research industry average of 12.53%.

What is DRIO's Price Target?

According to 1 Wall Street analyst that have issued a 1 year DRIO price target, the average DRIO price target is $2.00, with the highest DRIO stock price forecast at $2.00 and the lowest DRIO stock price forecast at $2.00.

The Wall Street analyst predicted that Dariohealth's share price could reach $2.00 by Mar 11, 2026. The average Dariohealth stock price prediction forecasts a potential upside of 177.78% from the current DRIO share price of $0.72.

What is DRIO's Earnings Per Share (EPS) forecast for 2025-2026?

(NASDAQ: DRIO) Dariohealth's current Earnings Per Share (EPS) is -$0.61. On average, analysts forecast that DRIO's EPS will be -$1.06 for 2025, with the lowest EPS forecast at -$1.06, and the highest EPS forecast at -$1.06. In 2026, DRIO's EPS is forecast to hit -$1.01 (min: -$1.01, max: -$1.01).

What is DRIO's forecast return on equity (ROE) for 2025-2027?

(NASDAQ: DRIO) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.